Xeris Biopharma Holdings, Inc. XERS R2KR3KPHARMA
Company Overview
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Why Investors Should Care
Revenue has grown at a 95.1% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $291.85M (+43.7% YoY); net profit $554.00K.
- Trailing 12 Months Year-on-year growth — revenue +28.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 95.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 95.07% |
| 1 Year: | 28.70% |
Stock Price Performance
| 1 Year: | +40.11% |
| 6 Months: | +68.60% |
| 3 Months: | +24.24% |
| 1 Month: | +13.97% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)54.24 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 95.1% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | XERS Xeris Biopharma Holdings, Inc. R2KR3KPHARMA | 10.20 | -102.00 | $1.86B | 0.00% | 9.09% | 4.05% | 95.07% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 9.40M | 8.05M | 8.91M | 11.06M | 22.07M | 25.31M | 29.73M | 33.20M | 38.01M | 48.32M | 40.64M | 48.06M | 54.27M | - | 60.12M | 71.54M | 74.38M | 85.81M | 83.13M | 92.10M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.73M | 11.90M | 11.00M | 10.95M | 10.57M | - |
| Gross Profit | - | - | 6.62M | - | - | 7.84M | - | - | - | - | - | - | - | - | - | - | 51.39M | 59.64M | 63.38M | 74.86M | 72.55M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 54.48M | 55.16M | 56.65M | 58.09M | 64.64M | - |
| Operating Income | - | - | -13.74M | -16.74M | -25.79M | -24.36M | -29.07M | -18.92M | -18.78M | -13.28M | -15.98M | -4.91M | -14.24M | -8.19M | -12.89M | - | -3.09M | 4.48M | 6.73M | 16.77M | 7.92M | 5.17M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.23M | 8.59M | 11.08M | 21.43M | 12.33M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.30M | 7.36M | 7.27M | 7.15M | 6.88M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -9.22M | -1.93M | 621.00K | 11.08M | 2.23M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Net Income | -29.18M | -24.10M | -16.00M | -18.41M | -27.52M | -26.01M | -33.71M | -26.18M | -21.83M | -16.83M | -19.84M | -12.19M | -18.98M | -15.01M | -15.74M | - | -9.22M | -1.93M | 621.00K | 11.08M | 2.23M | -31.10M |
| Diluted EPS | - | - | - | -0.30 | -0.41 | -0.39 | -0.25 | -0.19 | -0.16 | -0.12 | -0.14 | -0.09 | -0.14 | -0.10 | -0.11 | - | -0.06 | -0.01 | 0.00 | 0.06 | 0.01 | -0.18 |
| R&D Expense | - | - | 3.88M | 4.03M | 5.38M | 5.66M | 6.25M | 3.72M | 6.04M | 4.84M | 6.09M | 5.03M | 7.82M | 5.76M | 5.89M | - | 7.75M | 8.05M | 7.48M | - | 8.78M | 10.67M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 20.16M | - | 110.25M | 163.91M | 203.07M | 291.85M |
| Cost of Revenue | - | - | 22.63M | 28.64M | 36.83M | 42.57M |
| Gross Profit | - | - | 87.61M | 135.27M | 166.24M | 249.28M |
| Operating Expenses | - | - | 169.55M | 179.28M | 199.88M | 224.38M |
| Operating Income | -83.55M | - | -81.94M | -44.01M | -33.65M | 24.90M |
| EBITDA | - | - | -69.31M | -23.73M | -13.99M | 42.33M |
| Interest Expense | - | - | 14.10M | 26.61M | 30.48M | 29.08M |
| Pretax Income | - | - | -96.08M | -63.50M | -57.10M | 554.00K |
| Tax Provision | - | - | -1.42M | -1.25M | -2.27M | 0 |
| Net Income | -91.14M | - | -94.66M | -62.26M | -54.84M | 554.00K |
| Diluted EPS | - | - | -0.70 | -0.45 | -0.37 | 0.00 |
| R&D Expense | 20.92M | 25.16M | 20.97M | 22.34M | 25.56M | 31.16M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 159.15M | - | 344.52M | 322.60M | 323.06M | 383.53M |
| Current Assets | - | - | - | 186.82M | 156.26M | 167.66M | 240.31M |
| Cash & Equivalents | 19.52M | 37.60M | - | 121.97M | 67.45M | 71.62M | 111.04M |
| Inventory | - | - | - | 24.73M | 38.84M | 48.17M | 68.67M |
| Receivables | - | - | - | 30.83M | 39.20M | 40.41M | 51.05M |
| Total Liabilities | - | 125.39M | - | 299.33M | 329.38M | 352.68M | 369.84M |
| Current Liabilities | - | 28.21M | - | 73.62M | 95.19M | 100.44M | 109.57M |
| Long Term Debt | - | 87.02M | - | 187.07M | 190.93M | 217.01M | 220.34M |
| Total Debt | - | - | - | 198.06M | 229.19M | 271.45M | 258.10M |
| Total Equity | 14.44M | 33.76M | - | 45.19M | -6.78M | -29.61M | 13.69M |
| Shares Outstanding | - | - | - | 136.27M | 138.13M | 149.43M | 166.22M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -80.56M | - | -102.89M | -47.02M | -36.98M | 28.63M |
| Investing Cash Flow | -27.41M | - | 34.46M | -6.00M | 4.88M | -696.00K |
| Financing Cash Flow | 126.06M | - | 127.47M | -1.61M | 36.17M | 11.39M |
| Capital Expenditure | -377.00K | - | -524.00K | -2.26M | -868.00K | -696.00K |
| Free Cash Flow | -80.94M | - | -103.42M | -49.29M | -37.85M | 27.93M |
| Net Change in Cash | - | - | 59.04M | -54.64M | 4.07M | 39.32M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 79.5% | 82.5% | 81.9% | 85.4% |
| Operating Margin % | -414.5% | - | -74.3% | -26.8% | -16.6% | 8.5% |
| Net Margin % | -452.2% | - | -85.9% | -38.0% | -27.0% | 0.2% |
| ROE % | -270.0% | - | -209.5% | 917.9% | 185.2% | 4.0% |
| ROCE % | -63.8% | - | -30.2% | -19.4% | -15.1% | 9.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.97% | 14.53M | $152.23M |
| 2 | Shaw D.E. & Co., Inc. | 4.28% | 7.80M | $81.79M |
| 3 | Vanguard Capital Management LLC | 4.03% | 7.34M | $76.93M |
| 4 | State Street Corporation | 2.64% | 4.82M | $50.53M |
| 5 | Geode Capital Management, LLC | 2.59% | 4.72M | $49.45M |
| 6 | Nuveen, LLC | 2.41% | 4.39M | $45.96M |
| 7 | Rosalind Advisors, Inc. | 1.60% | 2.91M | $30.49M |
| 8 | Qube Research & Technologies Ltd | 1.59% | 2.89M | $30.33M |
| 9 | Vanguard Portfolio Management LLC | 1.44% | 2.63M | $27.52M |
| 10 | Wellington Management Group, LLP | 1.30% | 2.37M | $24.79M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for XERS
Xeris Biopharma Holdings, Inc. Estimates – NASDAQ:XERS - TradingView
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE5tZnNGQ2hZdml5UEt0cmgtTS04Mk5seWZPTnBrNVE1MlkxT0xqWkYtOUcxVGF5a2V5cFFXbkViSlI2MUVNQzBScDd1TnhacktqVDVGcExJUWJ3dkVlcmRjd1F6RFRlU1NGOXMtWlhUMVBaYkxyRU1IVw?oc=5" target="_blank">Xeris…
XERS Nov 2026 9.000 put (XERS261120P00009000) interactive stock chart - Yahoo Finance Australia
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE1NZHZxeURua1N3QnZ2Ml9nZU1hRWhlSFpvS1NhbTFVVU5nazN1WmhRQlZvbWZHeFd3aGRodnpROHBJaXl6eDZwdEhxb2luVmp2bkotZS1jVWRmbnZ4T2kzZ3A3d1A5SXdubkQ2SF9R?oc=5" target="_blank">XERS Nov 2026 9.000…
Gen Xers share 17 nostalgic dishes they ate growing up—and still make for dinner - Upworthy
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNWkdMQ2U3dVJuOXQwdHJleWpEejRzUzhaNnZDRVRFZGhSUDJueUpWdlZENW5FenlsU1VnQzhXb3c0V3RRMXlWeTQ4b0ZWV2xxVDV1NEJHb3pXUFBEQWJoVVZoWDNBSGhaSEM4RGxVcU9wZGpBM1ZrS1R0ZHEtTU9ITHN6czlpeVd3MnQyeV…
Xeris Biopharma Holdings Inc (XERS) Shares Surge 6.2% -- What GF Score of 65 Tells Investors - GuruFocus
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxOci1ZV0dzblF2UzY1Nk9TMDNDekptYzdnVTNoMml5ekJscWE0ZXZNSHRlbG1tVnBtQTFYTTZzd0p1ZE5CeDZaNG9BSnhIVlpkNDJVc0E0T0Z6ZGM3dUxaMDFnSk5EWGhUbUo2SXVCclBjMGFRUklkXzc1QVhpVnp1V05LZmNsT3ZtS0t4al…
XERS Nov 2026 7.500 put (XERS261120P00007500) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE04dkhtRlVCbjY5YS1YVDRmbjBHSzdtRTd3d0NkMmg5dUROaVoxZ19McWVrbW5LT0Npbzk2ejUzOWh5YVl6M3JXa09OTmMxZExoeUF3STE1RE84Nlhid19pbFN5OFpSQQ?oc=5" target="_blank">XERS Nov 2026 7.500 put (XERS…
XERS Nov 2026 9.000 put (XERS261120P00009000) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE5TVElXOFVGSXhXVjVrOUJHLXpJNXplXzBTVWx0Vm9KTzJSakM4N2k2MnV1RWItQkk4N1NsX2ZydU5xR0ZySmlGUzgwREtTZXBaRDBOUVJ4eDIwaWJoVjUyRGlRZFlzQQ?oc=5" target="_blank">XERS Nov 2026 9.000 put (XERS…
XERS — Frequently Asked Questions
What is the current share price of Xeris Biopharma Holdings, Inc. (XERS)?
As of 2026-10-23 16:27 PDT, Xeris Biopharma Holdings, Inc. (XERS) trades at $10.20 on NasdaqGS. Its 52-week range is $5.29 to $11.13.
What is the market capitalisation of XERS?
Xeris Biopharma Holdings, Inc. (XERS) has a market capitalisation of $1.86B on NasdaqGS.
What is the P/E ratio of XERS?
XERS trades at a trailing price-to-earnings (P/E) ratio of -102.00. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is -146.43.
What is the return on equity (ROE) of XERS?
XERS has a return on equity (ROE) of 4.05%. Its return on capital employed (ROCE) is 9.09%.
Is XERS a good stock to buy?
This page provides a data-driven analysis of Xeris Biopharma Holdings, Inc. (XERS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.